• Unrivaled resolution of structural variations, rearrangements, and exon duplicates
• Flexible workflow
• Combined breadth and depth
• Designed for biomarker analysis in clinical trials, treatment monitoring, and acquisition of drug resistance with a single blood draw
Available in RUO and CLIA-validated assay
From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE™ or PredicineATLAS™ focused pan cancer panels, based on tumor fraction from the sample.
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.